Drugs / MHS-1031
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT05556824 Comparator | Mar 2023 → May 2026 overdue | gastroesophageal reflux disease | Microbiome Health Sciences | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MHS-1031 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05556824 ↗ |
| Modality | Other / unclassified | “MHS-1031 is a specific proprietary digestion-resistant oligosaccharide carbohydrate that serves as a prebiotic.” NCT05556824 ↗ |